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LABORATORY INVESTIGATION
Identification of vasopressin and determination of its
corticomedullary levels in rat kidney tissue
KURAKAZU SHIMIzu, AKIHIDE NAKAO, TATSUYA NONAKA, and HIR0sHI OKA
First Department of Internal Medicine, University of Tokyo, Tokyo, Japan
Identification of vasopressin and determination of its corticomeduilary
levels in rat kidney tissue. To investigate the kidney tissue level of
arginine vasopressin (AVP), tissue AVP was extracted, identified and
assayed. Rat kidney tissue was separated into the papilla (P), medulla
(M.), and cortex (C). After homogenization, AVP was extracted with
acetone and determined by radioimmunoassay. Fractionation of the
tissue extract by Sephadex 025 column chromatography showed that
the peak of immunoreactive AVP was identical to that of synthetic
AVP. There was good correlation between bioassayable and immunoas-
sayable AVP for the tissue extracts. Tissue AVP concentrations (pg/g
wet weight) after 36 hr of dehydration were: F, 164.3 13.0; M, 93.8
8.4; and C. 28.9 3.9 with a plasma AVP (pg/mi) of 11.7 1.0 (mean
SE, N = 18). Thus, the papilla/plasma AVP concentration ratio was
high. When 251-AVP was administered, the papilla/plasma ratio was
very low. Under water diuresis, the tissue AVP level was very low. The
kidney tissue level of dDAVP, which was administered exogenously,
was much higher than that of AVP when compared at similar plasma
levels. Thus, the present study demonstrated the existence of a
corticomedullary concentration gradient of AVP with a medullary level
much higher than the plasma level. The accumulation of AVP seemed to
result from receptor-mediated processes, since 251-AVP. which is
biologically inactive and does not bind to hormone receptors, showed
only a slight accumulation. The higher tissue level of dDAVP suggested
that the tissue level was determined by the balance between accumula-
tion and inactivation, since dDAVP is known to be scarcely inactivated
in the kidney.
Identification de Ia vasopressine et determination de ses niveaux
cortico-médullaires dans le tissu renal de rat. Explorer le niveau tis-
sulaire renal d'arginine vasopressine (AVP), l'AVP tissulaire a Cté
extraite, identiflée et dosée. Le tissu renal a été sCparé en papille (P),
medulla (M), et cortex (C). Après homogenéisation, l'AVP a été
extraite avec de l'acCtone et dCterminCe par dosage radioim-
munologique. Le fractionnement de l'extrait tissulaire sur colonne de
chromatographie de SCphadex G25 a montré que le pie d'AVP
immunorCactive Ctait identique a celui de l'AVP synthCtique. Ii y avait
une bonne correlation entre l'AVP dosable biologiquement et im-
munologiquenient dans ces extraits tissulaires. Les concentrations
tissulaires d'AVP (pg'g de poids humide) après 36 heures de
deshydratation Ctaient: P. 164,3 13,0; M, 93.8 8,4; et C, 28,9 3.9
avec one AVP plasmatique (pg/mi) de 11,7 1,0 (moyenne SE, N =
18). Ainsi, Ic rapport de concentration d'AVP papille/plasma était
élevC. Quand de l"251-AVP était administrée, Ic rapport papille/plasma
Ctait trés bas. Lors d'une diurèse aqueuse, Ic niveau dAVP tissulaire
Ctait trés bas. Le niveau tissulaire renal de dDAVP, qui avait Cté
administré de facon exogène, Ctait bien plus élevé que celui de I'AVP
par rapport a un niveau plasmatique identique. Ainsi. cette étude a
démontrC l'existence d 'on gradient de concentration cortico-médullaire
d'AVP avec un niveau mCdullaire hien plus élevé que Ic niveau
plasmatique. L'accumulation d'AVP a semblC résulter de processus
ayant on rCcepteur pour mediateur puisque 251-AVP, qui est
hiologiquement inactive et ne se lie pas aux rCcepteurs hormonaux. na
présentC qu'une discrete accumulation. Le niveau tissulaire plus élevé
(IC dDAVP suggerait que Ic niveau tissulaire était déterminé par on
equilibre entre l'accumulation et l'inactivation Ia dDAVP étant connue
pour ktre faiblement inactivée par le rein.
It is a well-established fact that the kidney is a target organ of
vasopressin and that the first step of urinary concentration is
the binding of vasopressin with its hormone receptors. In
addition to being a target organ, the kidney removes vasopres-
sin from the circulation both via glomerular filtration and uptake
from peritubular sites [1, 2]. There is much evidence that
plasma vasopressin concentrations as low as a few picograms
per milliliter are enottgh to cause antidiuresis in humans and
animals. On the other hand, it has often been pointed out that
the vasopressin concentration required to obtain half-maximal
receptor occupancy in vitro is higher by several orders of
magnitude than the concentration of hormone in the blood [3,
4]. However, little is known about the renal tissue concentra-
tion of vasopressin. The above-mentioned considerations stim-
ulated us to try to measure this hormone concentration in
kidney tissue.
In this study, arginine vasopressin (AVP) was extracted from
rat kidney and identified. The tissue AVP level was assayed
under the conditions of urinary concentration and dilution.
Next, we examined the effect of exogenously administered
'251-AVP, which is biologically inactive and does not bind with
hormone receptor, on the tissue/plasma ratio. Further, dDAVP
(1 -deamino-8-D-arginine vasopressin), which is a synthetic ana-
logue of AVP and hardly inactivated in the kidney, was admin-
istered for the purpose of comparing the tissue levels of AVP
and dDAVP and examining the effect of dDAVP on the
endogenous AVP level.
Methods
Experimental protocol. All of the studies were performed on
Wistar strain rats weighing 250 to 350 g. The experiments with
renal tissue AVP determination were performed on three
groups of animals. Group I (N = 18) consisted of rats restricted
from drinking water for 36 hr but not from eating food: group 2
(N = 8), rats under normal hydration with free access to food
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and water; and group 3 (N = 8), rats under water diuresis
caused by administration of water to 5% of body weight by
stomach tube, twice, 75 and 30 mm before sacrifice.
Extraction ofAVPfro,n kidney tissue. The rats were sacri-
ficed by guillotine. Blood issuing from the trunk was collected
in chilled, heparinized tubes as the animals were exsanginated.
The bilateral kidneys were immediately removed. Each kidney
was sectioned with a sharp knife in a longitudinal plane, slightly
off-center, so that the papilla was exposed intact. Slices were
removed from the cortex, medulla (outer medulla), and papilla
(inner medulla). Slices of each tissue portion (weighing about
0.1 g) were put into pre-weighed, capped flasks containing 2 ml
of ice-cold acetone and reweighed. After 1 ml of 0.45% saline
was added, the contents of the flask were transferred to a glass
homogenizer and homogenized.
The homogenates were centrifuged at 3000 rpm at 4°C for 30
mm. The supernatant was mixed with 8 ml of cold petroleum
ether. The top phase was then removed by aspiration. The
remaining extract was frozen at —40°C and freeze-evaporated
using a Freeze Mobile-6 (Virtis Co., Inc., Gardiner, New
York, USA). The dried extracts were stored at —40°C. The
recovery rate of AVP added to the mixture of tissue and the
acetone before homogenization (50 pg/0.l g of tissue) was 67.8
5.5% for the papillary tissue, 86.1 1.1 for medullary tissue,
and 63.5 8.7% for cortical tissue (mean SD, N = 4).
Extraction ofAVP from plasma and urine. Heparinized blood
was centrifuged as soon as possible at 4°C. Urine samples were
obtained by direct bladder puncture immediately after sacrifice.
Plasma and urine were frozen at —40°C until extraction. The
extraction of AVP from plasma and urine was performed by a
modification [5] of the methods described by Husain et al [6]
and Robertson et al [7]. The recovery rate of the added AVP
was 66.7 3.4% for plasma AVP and 98.0 7.4% for urinary
AVP (mean SD, N = 10).
Gel chromatography of the kidney extract. AVP was ex-
tracted from 20 kidneys by the same methods as described
above, that is, for 1 g of tissue, 20 ml of acetone and 80 ml of
petroleum ether were used. The only exception was that 20 ml
of distilled water, instead of 0.45% saline, were added to the
mixture of tissue and acetone before homogenization. The dried
tissue extract was dissolved in 2 ml of 0.1% BSA and applied to
a 0.9 x 25 cm Sephadex G25 column and eluted with 0.01 M
phosphate buffer (pH 7.4). The eluate was collected in l-ml
aliquots and the AVP concentration in each fraction was
assayed. In the same way, synthetic AVP was fractionated.
Labeled marker ('251-AVP) was added to the extracts or syn-
thetic AVP before it was applied to the columns.
'251AVP injections. Rats under water restriction (N = 10,
the same condition as group 1) and rats under water diuresis (N
= 4, the same condition as group 3) received a subcutaneous
injection of '251-AVP (200 pg/100 g body weight, calculated from
the specific activity at the time of the experiments) into their
backs. Sixty minutes following the injection, the rats were
decapitated and exsanguinated. Blood samples and kidney
tissue slices were obtained; '251-AVP was extracted from
plasma and tissue as described previously. Immunoreactive
'251AVP cpm was determined as follows: The extract was
dissolved in 800 bd of RIA buffer and a 600-gd aliquot was mixed
with 200 il of excess AVP antibody (1:4000 final dilution). This
mixture was allowed to incubate for 24 hr at 4°C before
separating immunoreactive 1251-AVP from non-immunoreactive
1251 by the charcoal separation technique. The radioactivity of
the immunoreactive supernatant fraction was counted for 5 mm
and the tissue (c/min/g of wet weight) to plasma (c/mm/mi) ratio
of immunoreactive '251-AVP was calculated. In five experi-
ments, urinary immunoreactive '251-AVP was also counted to
calculate urinary '251-AVP clearance.
dDAVP and AVP injections. Rats restricted from drinking
water for 36 hr were injected either with (1) dDAVP (2.5, 12.5,
and 25 ng/100 g body weight, N = 5 in each group) or (2) AVP
(125 and 250 ng/lOO g body weight, N = 5 in each group). After
90 mm in the case of dDAVP and 30 mm in the case of AVP
(because of more rapid plasma disappearance in AVP than
dDAVP after injection), tissue AVP and dDAVP were extracted
as described above and their concentrations were determined.
Inactivation of AVP by kidney tissue. Kidney tissue slices
were homogenized with 25 m phosphate buffer (pH 7.4)
containing 0.5 mM ethylenediamine tetra-acetic acid (EDTA)
(10% wet wt/vol). The homogenates were then centrifuged for
90 mm at x 70,000g at 4°C, and the resulting supernatants were
used for the inactivation experiments.
Five-milliliter aliquots of the supernatant were transferred
separately into flasks (Erlenmeyer) and incubated at 37°C,
Synthetic AVP was added at a concentration of 250 pg/mI. After
intervals of 0, 15, 30 and 60 mm, 0.5-mi portions of the mixture
were removed for extraction and determination of the AVP
concentration.
Analytical methods. AVP concentrations in extracts of tis-
sue, plasma, and urine were determined by means of ra-
dioimmunoassay (RIA), as previously described by Shimizu
and Hoshino [5] and Shade and Share [8]. Briefly, iodination of
synthetic AVP (Sigma Chemical Company, St. Louis, Missouri,
USA; grade VI, 367 lU/mg) was performed according to the
method of Greenwood, Hunter, and Glover [9]. Synthetic AVP
(1.5 U) underwent reaction with 2 pCi of 125J (New England
Nuclear Corp., Boston, Massachusetts, USA). '251-AVP was
purified by applying the mixture to a 0.8 x 15 cm chromatog-
raphy column of DEAE cellulose and eluting it with 0.02 M
ammonium acetate. Then a 1-mI peak fraction was applied to a
0.9 x 25 cm Sephadex G 25 column and eluted with 0.01 M
phosphate buffer (pH 7.4). The specific activity of the '251-AVP
used for RIA and for the injection experiments was 1043 104
pCi/gig (mean SE, N = 7). The anti-AVP antibody was
produced in New Zealand white rabbits by injecting AVP
conjugated with bovine serum albumin (BSA).
In preparing the standard curves and assay, all dilutions were
made with 0.1 M phosphate buffer (pH 7.6) containing 0.3%
NaC1 and 0.1% BSA. Unlabelled AVP, 0.1 ml of '251-AVP (3000
cpm) and 0.2 ml of antibody (final dilution 1:180,000) were
added to tubes containing the buffer. The final volume was 0.9
ml. In the assay, dried extract was redissolved in assay buffer
and 0.2 to 0.4 ml of the mixture was used for the assay. The
assay tubes were incubated at 4°C for 3 days. The separation of
bound from free 1251-AVP was carried out using the BSA-coated
charcoal method [81. 125J was counted using an automatic
well-counter.
The sensitivity of the assay was 0.5 to 1.0 pg per assay tube.
The intraassay coefficient of variation was 7.1% in the assay of
an identical sample containing about 2.1 pg/ml; the interassay
pg
Fig. 1. A Standard curve ofAVP (0) and dDAVP (•) obtained with
antibody A. B/Bo (cpm bound over cpm bound at the zero dose) is
plotted versus the log of the dose of AVP or dDAVP added. B Standard
curve ofAVP and dDAVP obtained with antibody B.
coefficient of variation was 7.8%. Oxytocin did not significantly
replace '251-AVP.
dDAVP was extracted and assayed by the same method used
for AVP [10]. In the assay, '251-AVP was used instead of
'251-dDAVP, because there was no significant difference in the
preliminary assay results between '251-AVP and '251-dDAVP.
We used two kinds of vasopressin antiserum: an AVP anti-
serum (antibody A) that barely crossreacts with dDAVP (Fig.
1A), and an LVP antibody (antibody B), a gift of Dr. L. Share
[8], that completely crossreacts with dDAVP (Fig. 1B). There-
fore, dDAVP concentration was estimated by subtracting vaso-
pressin concentration (AVP concentration) determined using
antibody A from that (AVP + dDAVP concentration) deter-
mined using antibody B. There was no significant difference in
the recovery of extraction, sensitivity, or reproducibility of the
assay between AVP and dDAVP [101.
Some of the tissue extracts were assayed for AVP by
both RIA and bioassay methods. Bioassay was carried out
by the method reported by Share [11] in hydrated, ethanol-
anesthetized rats using a sensitive conductivity meter.
Osmolality of plasma and urine were determined using an
Advanced Osmometer (Model 3L, Advanced Instruments Inc.,
Needhamheight, Massachusetts, USA). Creatinine was deter-
mined by a biochemical automatic analyzer (Model JCA-H12,
Japan Electron Optical Laboratory Corp., Akishima, Japan).
Results
Gel chromatography. The elution patterns on Sephadex G25
filtration of synthetic AVP and the immunoreactive material in
tissue and urine extracts are shown in Figure 2. The synthetic
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Fig. 2. Immunoreactive AVP concentration in Sephadex G 25 eluates of
synthetic AVP and extracts of kidney tissue and urine. A small amount
of '251-AVP was added to the synthetic AVP and tissue extracts before
it was applied to the column.
AVP emerged as a single peak before the '251-AVP. The main
peak of the tissue immunoreactive material coincided with that
of the synthetic AVP. Further, the elution pattern of the
immunoreactive material from the urine extracts was identical
to that of the synthetic AVP.
Relation between RIA and bioassay. As shown in Figure 3,
there was a good correlation between RIA and bioassay for the
tissue AVP concentrations. The RIA analysis was about 80% of
the bioassay analysis in paired samples.
In vitro inactivation of AVP. When synthetic AVP was
incubated with the supernatant of the tissue homogenates in
phosphate buffer, AVP was rapidly inactivated (see Table 1).
This was in sharp contrast to the good AVP recovery rate in the
process of extraction, in which the kidney tissues and AVP
were homogenized in acetone.
Tissue AVP concentrations. AVP concentrations of kidney
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Tissue 0 5 10 15
Papilla 100.6 3.9 40.2 2.9 25.3 2.4 15.8 2.9
Medulla 78.6 + 4.4 37.2 3.0 19.4 0.4 16.1 2.1
Cortex 75.9 4.2 39.2 1.7 22.7 2.4 21.4 2.6
a The values are the AVP concentration (pg/mi) in the supernatants (mean SD of four measurements).
Table 2. AVP concentrations in tissue and plasma under the three experimental conditions (mean SE)
Tissue AVP
Papilla Medulla
Condition pg/g wet weight
Dehydration, 36 hr 164.3 13.0(N = 18)
Normal hydration(N = 8)
Water diuresis
(N =8)
73.3 9.1
9.9 3.1
41.6 8.6
17.2 3.3
30.2 4.4 2.7 + 0.34
<0.5
tissues under the three experimental conditions are shown in
Table 2. In group 1 (water restriction), the average plasma AVP
concentration was Il .7 pg/mI, whereas the average tissue AVP
concentration was a high 164.3 in the papilla, 93.8 in medulla,
and 28.9 pg/g of wet weight in cortex. Thus, a concentration
gradient from the cortex to the papilla was evident. In group 3
(water diuresis). the plasma AVP concentration was less than
0.5 pg/mi (undetectable) and the tissue AVP concentrations
were greatly reduced. In group 2 (normal hydration), the plasma
and tissue AVP concentrations showed values between those of
groups I and 3.
In Table 3 under "Endogenous AVP," the tissue AVP
concentrations (pg/g) are shown as a ratio to plasma AVP
concentrations (pg/mi). The tissue/plasma ratio of endogenous
AVP was high in group I, but still higher in group 2, since the
plasma AVP level in group 2 was much lower than that in group
The results of the '251-AVP injection experiments are shown
in Table 3 under 2sIAVP. In contrast to the endogenous AVP,
the tissue/plasma ratio of 251-AVP was markedly low. When
calculated from the specific activity, the plasma concentration
of'251-AVP was found to be 3.19 0.11 pg/mI (mean + SE, N
= 10) under these experimental conditions. The ratio of AVP
clearance to creatinine clearance (CAVP/CCr). which is an ap-
propriate index of fractional AVP excretion, was 31.6 3.0%
for endogenous AVP and 26.4 4.1% for '251-AVP (mean
SE, N = 5).
Table 4 shows the tissue and plasma concentration of dDAVP
and AVP when they were administered exogenously. The tissue
concentration of dDAVP was much higher than AVP, when
compared at a similar level of plasma concentration. The tissue
concentration of endogenous AVP was not reduced by dDAVP
administration despite the existence of a level of dDAVP in the
tissue that was several times higher. The papillary concentra-
tions of AVP and dDAVP increased abruptly as the plasma
concentration increased from a low level, but the rate of
increase dropped at higher plasma levels. l'herefore, the
tissue/plasma ratio of vasopressin decreased progressively as
the plasma concentration increased (Tables 2 and 4).
Discussion
This study demonstrates the existence of measurable AVP in
the rat kidney. There was a steep corticomedullary gradient in
tissue AVP level, with meduilary AVP substantially higher than
the plasma level. Moreover, the AVP concentration gradient
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Table 1. The immunological reactivity of AVP after in vitro incubation with the supernatants of kidney tissue homogenatesa
Duration of incubation, mm
30
13.9 3.4
13.2 3.0
16.3 2.5
60
8.3 2.6
8.3 2.5
15.0 0.4
Cortex
93.8 8.4 28.9 3.9 11.7 1.0
Plasma
AVP
pg/mi
V 0.803x 3 06
0.92
12.5 2.7
0
120
100
80
I
Fig. 3. Correlation between bioa say and RIA. tissue extract samples
were subjected to AVP measurement by bioassay and RIA. AVP is
expressed as picograms per gram of wet weight of tissue.
20 40 60 80 100 120
Bioassay AVP, ,.aU g wet wt
Condition
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Table 3. Tissue (pg/g wet weight) to plasma (pg/mi) AVP concentration ratio of endogenous AVP and '251-AVP
showed a marked change during antidiuresis and water diuresis.
The tissue level of dDAVP was much higher than that of AVP,
when compared at similar plasma levels.
Tissue AVP was extracted and assayed by RIA. The identity
of the immunoreactive material of the tissue extracts to AVP
was supported by the fact that the material did not differ
chromatographically from synthetic AVP and that a good
correlation existed between bioassay and RIA of the material.
It is possible that metabolities of AVP in the kidney were also
assayed by RIA, but this is unlikely for the following reasons:
(1) AVP metabolites are biologically inactive, but in this study
there was a good correlation between bioassay and RIA. (2)
When incubation with kidney tissue homogenates was used,
synthetic AVP was rapidly converted to an immunologically
unreactive material, suggesting that the AVP antibody used in
this assay did not crossreact with AVP metabolites in the
kidney. (3) The AVP antibody did not crossreact with oxytocin
either.
In contrast to endogenous AVP, no significant accumulation
f 125jyp occurred in the renal medulla with a similar
fractional AVP excretion between endogenous AVP and 125I
AVP. It is known and recently confirmed by Weitzman and
Fisher [12] that '251-AVP is biologically inactive and does not
show specific binding to the renal medullary plasma membrane.
Furthermore, they showed in the dog that AVP differs from
1251Avp by a much reduced distribution volume and metabolic
clearance rate. They suggested that plasma AVP clearance
involved at least two components: receptor-mediated
peritubular uptake of AVP (whether the receptor is tubular
or vascular) and non-receptor-mediated glomerular filtration,
and that '251-AVP clearance is mediated solely by the latter
pathway.
The results of this study suggest that the accumulation of
AVP in the renal medulla was receptor-mediated and might
proceed via uptake of AVP from the peritubular circulation.
lt has been shown that dDAVP has a much longer antidiuretic
effect and much slower plasma disappearance rate than AVP
when injected intravenously [10, 13, 141 and that dDAVP is
hardly inactivated by the kidney tissue homogenate, whereas
AVP is rapidly inactivated [10]. It was also reported that the
binding affinity of AVP to membrane receptors was not so
different from that of dDAVP [15].
The results of the dDAVP experiments in this study are
Tissue to plasma concentration ratio of AVP
Papilla, pglg Medulla, pg/g Cortex, pg/g
Plasma, pg/mi Plasma, pg/mi Plasma, pg/mi
Endogenous AVP
Dehydration, 36 hr 17.0 2.6 9.1 1.5 2.1 0.22
(N = 18)
Normal hydration 34.4 7.6 17.9 6.1 14.1 3.0
(N =8)
1251AVP
Dehydration, 36 hr 2.26 1.2 1.21 0.11 1.89 0.12
(N = 10)
Water diuresis 1.15 0.06 0.77 0.08 1.97 0.15
(N =4)
Table 4. Tissue and plasma level of AVP and dDAVP
Condition Dosage
Papilla Medulla Cortex Plasma
pg/miHormone pg/g wet weight
Control AVP 149 15 108 11 23.8 4.3 12.3 1.2
dDAVP 2.5 ng/100 g AVP 165 11 112 10 32.8 3.1 11.8 0.7
Injection dDAVP 189 22 179 16 60.3 4.3 2.7 0.5
dDAVP 12.5 ng/lOO g AVA 226 21 178 13 77.5 4.5 12.4 1.0
Injection dDAVP 2456 192 2775 477 746 44 42.3 4.9
dDAVP 25.0 ng/l00 g AVP 252 12 219 11 61.3 1.3 16.6 1.4
Injection dDAVP 2922 239 2967 118 776 81 87.8 6.5
AVP 125 ng/l00 g AVP 398 40 363 33 108 8.0 84.3 6.4
Injection
AVP 250 ng/lOO g AVP 489 44 438 60 221 18 114 17
Injection
Abbreviations: Control, endogenous AVP level in dehydration; dDAVP Injection, effect on endogenous
exogenous AVP on tissue and plasma AVP level.
a Values are mean SE; N = 5.
AVP level; AVP Injection, effect of
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consistent with a slow inactivation rate for dDAVP and suggest
that the tissue level of vasopressin is determined by the balance
between tissue uptake and elimination.
Our study determined the corticomedullary level of AVP and
dDAVP in the rat kidney and presented evidence for the
medullary accumulation of vasopressin. Further studies are of
course necessary to define the exact mechanisms involved and
the physiological significance of this phenomenon.
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